Study Objective To investigate the influence of single nucleotide polymorphisms (SNP s) in
genes encoding metabolizing enzymes (CYP 2C8, CYP 2J2, and UGT 2B7) and …

Monitoring of immunosuppressive drugs, such as calcineurin and mTOR inhibitors, is
essential to avoid undesirable kidney transplant outcomes. Polymorphisms in …

Several candidate genes have been proposed as potential biomarkers for altered
pharmacodynamics or pharmacokinetics of immunosuppressive drugs. However, there is …

Lung transplant patients present important variability in immunosuppressant blood
concentrations during the first months after transplantation. Pharmacogenetics could explain …

The current literature has shown disparity as to which are the most important polymorphisms
affecting the metabolism of immunosuppressants. Although pharmacogenomics has the …

Among the immunosuppressive drugs currently used in solid-organ transplantation, the
calcineurin inhibitors cyclosporine and tacrolimus, and the mammalian target of rapamycin …

Objective: Tacrolimus is an immunosuppressive drug with a narrow therapeutic range and
wide interindividual variation in its pharmacokinetics. Cytochrome P450 (CYP) 3A and P …

The promise of drug individualization through pharmacogenomics will be evident initially in
those patients who have the poorest therapeutic response or most severe adverse drug …

Many pharmacogenomic predictors of drug response are now available, and include both
drug metabolism‐disposition factors and drug targets. Information on statistical approaches …

Methods. Genotypes for 86 renal transplant patients who received SRL-based maintenance
immunosuppressive therapy were determined using polymerase chain reaction followed by …